Revenue GrowthShield's 2024 trading update sees the company expect to deliver $32.2m of revenues for 2024, driven primarily by US Accrufer sales which grew 153%.

Bears Say

Cash Flow ConcernsStrong sales growth for Accrufer is still required to achieve the goal of cashflow breakeven, and funding does remain tight.

Prescription VolumeThe increase in NSP offsets a 6% decrease in prescription volumes QoQ, a significant slowdown vs Q2 and Q3 which delivered more than 20% prescription growth.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

0.06% Insiders

―

Mutual Funds

― Other Institutional Investors

99.94% Public Companies and

Individual Investors

Detailed Ownership Overview >

1JS FAQ

What was Shield Therapeutics’s price range in the past 12 months?

Shield Therapeutics lowest stock price was €0.02 and its highest was €0.07 in the past 12 months.

What is Shield Therapeutics’s market cap?

Shield Therapeutics’s market cap is €31.73M.

When is Shield Therapeutics’s upcoming earnings report date?

Shield Therapeutics’s upcoming earnings report date is Sep 04, 2025 which is in 70 days.

How were Shield Therapeutics’s earnings last quarter?

Shield Therapeutics released its earnings results on Apr 24, 2025. The company reported -€0.013 earnings per share for the quarter, beating the consensus estimate of -€0.016 by €0.003.

Is Shield Therapeutics overvalued?

According to Wall Street analysts Shield Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shield Therapeutics pay dividends?

Shield Therapeutics does not currently pay dividends.

What is Shield Therapeutics’s EPS estimate?

Shield Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Shield Therapeutics have?

Shield Therapeutics has 1,041,690,400 shares outstanding.

What happened to Shield Therapeutics’s price movement after its last earnings report?

Shield Therapeutics reported an EPS of -€0.013 in its last earnings report, beating expectations of -€0.016. Following the earnings report the stock price went down -19.355%.

Which hedge fund is a major shareholder of Shield Therapeutics?

Currently, no hedge funds are holding shares in DE:1JS

Shield Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-396.71%

Trailing 12-Months

Asset Growth

19.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shield Therapeutics

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.